10 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
1326634	38	Reversible inhibitors of the gastric (H+/K+)-ATPase. 3. 3-substituted-4-(phenylamino)quinolines.	Smithkline Beecham Pharmaceuticals R&D
	7	Novel 4-substituted pyridine derivatives: Practical derivatization and biological profiles of reversible H+/K+-ATPase inhibitors	TBA
	1	Silyl ethers of cycloheptene, novel proton pump inhibitors obtained during the total synthesis of the scopadulcic acids	TBA
32030976	66	Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.	University of Chemistry and Technology Prague
9934482	3	(2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6- pentamethylpiperidin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase.	Smithkline Beecham Research Unit
9022797	24	Nicotinamide derivatives as a new class of gastric H+/K(+)-ATPase inhibitors. 1. Synthesis and structure-activity relationships of N-substituted 2-(benzhydryl- and benzylsulfinyl)nicotinamides.	Dainippon Pharmaceutical
8558532	53	2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6-tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors.	Tanabe Seiyaku
7629814	66	Reversible inhibitors of the gastric (H+/K+)-ATPase. 5. Substituted 2,4-diaminoquinazolines and thienopyrimidines.	Smithkline Beecham Pharmaceuticals R&D
7629813	125	Reversible inhibitors of the gastric (H+/K+)-ATPase. 4. Identification of an inhibitor with an intermediate duration of action.	Smithkline Beecham Pharmaceuticals R&D
1848293	24	Studies on (H(+)-K+)-ATPase inhibitors of gastric acid secretion. Prodrugs of 2-[(2-pyridinylmethyl)sulfinyl]benzimidazole proton-pump inhibitors.	Upjohn